Recently, Guangzhou baiyunshan Pharmaceuticals Group Co., Ltd. (referred to as "the Company")'s subsidiary, Guangzhou Baiyunshan Pharmaceuticals Group Co., Ltd. baiyunshan Pharmaceutical Factory (referred to as "baiyunshan Pharmaceutical Factory") received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration (referred to as "NMPA").
Baiyunshan Pharmaceutical Factory obtained the "Drug Supplement Application Approval Notice" for citric acid sildenafil tablets this time, enriching the variety of its pharmaceutical products, which is beneficial for enhancing the Company's competitiveness in the pharmaceutical market. Baiyunshan Pharmaceutical Factory will carry out production in accordance with relevant requirements and market demands. Baiyunshan Pharmaceutical Factory obtained the "Drug Supplement Application Approval Notice" for mulberry chrysanthemum granules this time, improving the safety information of the product, which is beneficial for enhancing the market competitiveness of the product. Obtaining the above-mentioned Drug Supplement Application Approval Notices this time has no significant impact on the Company's current performance.
